Polymer-bound camptothecin: Initial biodistribution and antitumour activity studies

Journal of Controlled Release

Volumn 65, Issue 1-2, 2000, Pages 105-119

  Caiolfa, V R ^a   Zamai, M ^a   Fiorino, A ^a   Frigerio, E ^b   Pellizzoni, C ^b   D'Argy, R ^b   Ghiglieri, A ^b   Castelli, M G ^b   Farao, M ^a   Pesenti, E ^a   Gigli, M ^c   Angelucci, F ^a   Suarato, A ^a  

^a Discovery Research Oncology   (Italy)

^b Global Drug Metabolism Department   (Italy)

^c Pharmaceutical Development   (Italy)

Author keywords

Camptothecin; Drug delivery systems; Polymeric carriers

Indexed keywords

CAMPTOTHECIN; DNA TOPOISOMERASE; HYDROXYL GROUP; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE S PHASE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG HYDROLYSIS; DRUG STRUCTURE; ENZYME INHIBITION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR REGRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AUTORADIOGRAPHY; BUFFERS; CAMPTOTHECIN; DELAYED-ACTION PREPARATIONS; HT29 CELLS; HUMANS; HYDROLYSIS; INJECTIONS, INTRAVENOUS; KINETICS; METHACRYLATES; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; POLYMERS; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 0033997597     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(99)00243-6     Document Type: Article

References (26)

1. Hsiang Y.H., Liu L.F., Wall M.E., Wani M.C., Nicholas A.W., Manikumar G., Kirschenbaum S., Silber R., Potmesil M. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin. Cancer Res. 49:(16):1989;4385-4389.
2. Hertzberg R.P., Caranfa M.J., Hecht S.M. On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry. 28:1989;4629-4638.
3. Kingsbury W.D., Boehm J.C., Jakas D.R., Holden K.G., Hecht S.M., Gallagher G., Caranfa M.J., McCabe F.L., Faucette L.F., Johnson R.K., Hertzberg R.P. Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumour activity. J. Med. Chem. 34:1990;98-107.
4. Giovanella B.C., Stehlin J.S., Wall M.E., Wani M.C., Nicholas A.W., Liu L.F., Silber R., Potmesil M. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science. 246:1989;1046-1048.
5. Giovanella B.C., Hinz H.R., Kozielsi A.J. Jr., Stehlin J.S., Silber R., Potmesil M. Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin. Cancer Res. 51:1991;3052-3055.
6. Schaeppi U., Fleischman R.W., Cooney D.A. Toxicity of camptothecin (nsc-100880). Cancer Chemother. Rep. 2:1974;25-36.
7. Guarino A.M., Anderson J.B., Starkweather D.K., Chignell C.F. Pharmacologic studies of camptothecin (nsc-100880): distribution, plasma protein binding, and biliary excretion. Cancer Chemother. Rep. 57:1973;125-140.
8. Vasey P.A., Kaye S.B., Morrison R., Twelves C., Wilson P., Duncan R., Thomson A.H., Murray L.S., Hilditch T.E., Murray T., Burthes S., Fraier D., Cassidy J. Phase I clinical and pharmacokinetic study of PK1 (N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin). First member of a new class of chemotherapeutic agents - drug-polymer conjugates. Clin. Cancer Res. 5:1999;83-93.
9. Seymour L.W., Duncan R., Kopecková P., Kopečeck J. Daunomycin- and adriamycin-N-(2-hydroxypropyl)methacrylamide copolymer conjugates; toxicity reduction by improved drug-delivery. Cancer Treat. Rev. 14:(3-4):1987;319-327.
10. Putnam D., Kopečeck J. Polymer conjugates with anticancer activity. Adv. Polym. Sci. 122:1995;55-123.
11. Peterson C.M., Lu J.M., Sun Y., Peterson C.A., Shiah J.G., Straight R.C., Kopečeck J. Combination chemotherapy and photodynamic therapy with N-(2-hydroxypropyl) methacrylamide copolymer-bound anticancer drugs inhibit human ovarian carcinoma heterotransplanted in nude mice. Cancer Res. 56:1996;3980-3985.
12. Kopeček J., Bazilová H. Poly(N-(2-hydroxypropyl)methacrylamide). I. Radical polymerization and copolymerization. Eur. Polym. J. 9:1973;7-14.
13. Kopečeck J. Reactive copolymers of N-(2-hydroxypropyl)methacrylamide with N-methacryloylated derivatives of L-leucine and L-phenylalanine, 1. Preparation, characterization, and reactions with diamines. Makromol. Chem. 178:1977;2169-2183.
14. Kopečeck J., Rejmanová P. Reactive copolymers of N-(2-hydroxypropyl) methacrylamide with N-methacryloylated derivatives of L-leucine and L-phenylalanine II. Reaction with the polymeric amine and stability of crosslinks towards chymotrypsin in vitro. J. Polym. Sci. Polym. Symp. 66:1979;15-32.
15. Mendichi R., Rizzo V., Gigli M., Giacometti Schieroni A. Molecular characterization of polymeric antitumour drug carriers by size exclusion chromatography and universal calibration. J. Liq. Chrom. Relat. Technol. 19:(10):1996;1591-1605.
16. Mendichi R., Rizzo V., Gigli M., Razzano G., Angelucci F., Giacometti Schieroni A. Molar mass distribution of a polymer-drug conjugate containing the antitumour drug paclitaxel by size exclusion chromatography and universal calibration. J. Liq. Chrom. Relat. Technol. 21:(9):1998;129-130.
17. Ahmed A.E., Jacob S., Au W.W. Quantitative whole body autoradiographic disposition of glycol heter in mice: effect of route of administration. Fundam. Appl. Pharmacol. 22:1994;266-276.
18. Duncan R., Cable H., Lloyd J., Rejmanová P., Kopečeck J. Design of oligopeptide side-chains in poly[N-(2-hydroxypropyl)methacrylamide] copolymers to promote efficient degradation by lysosomal enzymes. Makromol. Chem. 184:1983;1997-2008.
19. Putnam D.A., Shiah J.G., Kopečeck J. Intracellularly biorecognizable derivatives of 5-fluorouracil. Biochem. Pharmacol. 52:1996;957-962.
20. Nichifor M., Schacht E.H., Seymour L.M. Macromolecular prodrugs of 5-fluorouracil. 2: Enzymatic degradation. J. Control. Release. 39:1996;79-92.
21. Supko J.G., Malspeis L. Pharmacokinetics of the 9-amino and 10,11-methylenedioxy derivatives of camptothecin in mice. Cancer Res. 53:1993;3062-3069.
22. M. Rowland, T.N. Tozer, Clinical Pharmacokinetics, Concepts and Applications, Williams and Wilkins (publ.), 3rd Edition, 1995.
23. 3H]-camptothecin distribution and tumour uptake in CASE-bearing nude mice: whole-body autoradiographic studies. Cancer Chemother. Pharmacol. 39:1996;122-130.
24. 3H]-labelled camptothecins. J. Label. Comp. Radiopharm. 38:(8):1996;733-742.
25. Seymour L.W., Ulbrich K., Kopečeck J., Strohalm J., Duncan R. The pharmacokinetics of polymer-bound adriamycin. Biochem. Pharmacol. 39:(6):1990;1125-1131.
26. Wu J., Akaike T., Maeda H. Modulation of enhanced permeability in tumours by a bradykinin antagonist, a cycloxygenase inhibitor, and nitric oxide scavenger. Cancer Res. 231:1999;158-165.